Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 21 小时前评分70
正文 · 机器翻译
KEYNOTE-B49：#ESMO26
在既往接受过治疗的 HR+/HER2− 转移性乳腺癌中，pembrolizumab + 化疗改善了 PFS（HR 0.74；6.7 vs 6.0 个月），且 99% 的患者既往曾接受过 CDK4/6 抑制剂治疗。
https://www.annalsofoncology.org/article/S0923-7534(26)08077-4/abstract
#BreastCancer @OncoAlert #BCSM @myESMO
90 浏览 · 6 赞 · 4 转发 · 1 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org帖内回复
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO The 24-month PFS rates (14.1% vs 3.5%) suggest durable control in a subset. However, the modest median gain, immune-related toxicity, and pending mature OS data warrant caution before routine adoption.
来源：Aya Mohamed | MSc, MD 🎗 · x.com